Guardant Health
GH
$170.69
+1.67%
Guardant Health, Inc. is a precision oncology company specializing in liquid biopsy tests for cancer detection, monitoring, and treatment guidance, operating in the medical diagnostics and research industry. As a market leader in liquid biopsy, its distinct competitive identity is anchored by its comprehensive portfolio, including Guardant360 for genomic profiling, Reveal for molecular residual disease, and Shield for colorectal cancer screening. The current investor narrative is centered on the company's accelerating revenue growth, driven by the recent FDA approval of an expanded liquid biopsy test, which solidifies its market leadership and creates a new growth catalyst, while the company continues to navigate its path to profitability amid substantial R&D and commercialization investments.…
GH
Guardant Health
$170.69
Related headlines
GH 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Guardant Health's 12-month outlook, with a consensus price target around $194.29 and implied upside of +13.8% versus the current price.
Average Target
$194.29
0 analysts
Implied Upside
+13.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $225
Analyst target range
The target price range spans from a low of $105.00 to a high of $225.00, indicating a wide dispersion of expectations. The high target of $225 assumes continued rapid adoption of Shield and Guardant360, potential margin expansion, and successful execution of the FDA-approved expanded test, while the low target of $105 may price in competitive pressures, reimbursement challenges, or slower-than-expected growth. Recent institutional ratings have been consistently positive, with firms like Canaccord Genuity, Morgan Stanley, and Citigroup reaffirming Buy or Overweight ratings in July 2026, suggesting a stable bullish sentiment. The wide spread between low and high targets highlights the uncertainty surrounding the company's long-term profitability and market share in the evolving liquid biopsy landscape.
GH Technical Analysis
Guardant Health is in a powerful sustained uptrend, with the stock price surging 178.5% over the past year, significantly outperforming the S&P 500's 20.5% gain. Currently trading at $170.69, the stock is near the upper end of its 52-week range, at approximately 96.7% of the range between the low of $53.40 and high of $176.58. This positioning near the highs indicates strong momentum and investor confidence, though it also suggests the stock may be overextended in the short term, warranting caution for potential pullbacks.
Beta
1.59
1.59x market volatility
Max Drawdown
-33.0%
Largest decline past year
52-Week Range
$53-$177
Price range past year
Annual Return
+178.5%
Cumulative gain past year
| Period | GH Return | S&P 500 |
|---|---|---|
| 1m | +13.2% | +3.6% |
| 3m | +43.5% | +2.7% |
| 6m | +65.6% | +11.4% |
| 1y | +178.5% | +18.7% |
| ytd | +67.8% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GH Fundamental Analysis
Guardant Health's revenue is growing rapidly, with Q1 2026 revenue of $301.7 million, representing a 48.3% year-over-year increase, accelerating from the 38.4% growth in Q4 2025 and 14.2% in Q1 2025. The Oncology segment is the primary driver, contributing $205.0 million, followed by Screening at $41.6 million, Biopharma & Data at $53.0 million, and Licensing & Other at $2.1 million. This robust growth trajectory underscores the successful commercialization of its liquid biopsy tests, particularly the Shield screening test, which is gaining market traction.
Quarterly Revenue
$301665000.0B
2026-03
Revenue YoY Growth
+48.3%
YoY Comparison
Gross Margin
65.2%
Latest Quarter
Free Cash Flow
$-224832000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GH Overvalued?
Given Guardant Health's negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, as earnings-based multiples are not meaningful. The trailing PS ratio stands at 13.0x, while the forward PS ratio is not directly provided, but the EV/Sales ratio of 19.6x indicates a premium valuation. The gap between the trailing PS and EV/Sales suggests the market is pricing in significant future growth, as the enterprise value includes debt and cash adjustments, reflecting expectations of continued revenue expansion.
PE
-30.8x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-37.8x
Enterprise Value Multiple